Format

Send to

Choose Destination
Radiother Oncol. 2017 Apr;123(1):158-163. doi: 10.1016/j.radonc.2017.01.015. Epub 2017 Feb 9.

Clinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancer.

Author information

1
Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: anraml@rm.dk.
2
Department of Oncology, Aarhus University Hospital, Denmark.
3
Department of Radiation Oncology, Leiden University Medical Center, The Netherlands.
4
Department of Oncology, Aarhus University Hospital, Denmark; Department of Medical Physics, Aarhus University Hospital, Denmark and Heidelberg, Institute for Radiation Oncology (HIRO), Germany.

Abstract

PURPOSE:

To implement coverage probability (CovP) for dose planning of simultaneous integrated boost (SIB) of pathologic lymph nodes in locally advanced cervical cancer (LACC).

MATERIAL AND METHODS:

CovP constraints for SIB of the pathological nodal target (PTV-N) with a central dose peak and a relaxed coverage at the perimeter were generated for use with the treatment planning system Eclipse: PTV-N D98 >90%, CTV-N D98 >100% and CTV-N D50 >101.5% of prescribed dose. Dose of EBRT was 45Gy/25 fx with a SIB of 55-57.5Gy depending on expected dose from brachytherapy (BT). Twenty-five previously treated patients with 47 boosted nodes were analysed. Nodes were contoured on cone beam CT (CBCT) and the accumulated dose in GTV-NCBCT and volume of body, pelvic bones and bowel receiving >50Gy (V50) were determined.

RESULTS:

Nearly all nodes (89%) were visible on CBCT and showed considerable concentric regression during EBRT. Total EBRT and BT D98 was >57 GyEQD2 in 98% of the visible nodes. Compared to treatment plans aiming for full PTV-N coverage, CovP significantly reduced V50 of body, bones and bowel (p<0.001) CONCLUSION: CovP is clinically feasible for SIB of pathological nodes and significantly decreases collateral SIB dose to nearby OAR.

KEYWORDS:

Cervical cancer; Coverage probability; Nodal boosting; Radiotherapy

PMID:
28190601
DOI:
10.1016/j.radonc.2017.01.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center